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Friedreich's ataxia induced pluripotent stem cell-derived cardiomyocytes display
electrophysiological abnormalities and calcium handling deficiency
Abstract
We sought to identify the impacts of Friedreich's ataxia (FRDA) on cardiomyocytes. FRDA is an autosomal
recessive degenerative condition with neuronal and non-neuronal manifestations, the latter including
progressive cardiomyopathy of the left ventricle, the leading cause of death in FRDA. Little is known about
the cellular pathogenesis of FRDA in cardiomyocytes. Induced pluripotent stem cells (iPSCs) were derived
from three FRDA individuals with characterized GAA repeats. The cells were differentiated into
cardiomyocytes to assess phenotypes. FRDA iPSC- cardiomyocytes retained low levels of FRATAXIN
(FXN) mRNA and protein. Electrophysiology revealed an increased variation of FRDA- cardiomyocyte
beating rates which was prevented by addition of nifedipine, suggestive of a calcium handling deficiency.
Finally, calcium imaging was performed and we identified small amplitude, diastolic and systolic calcium
transients confirming a deficiency in calcium handling. We defined a robust FRDA cardiac-specific
electrophysiological profile in patient-derived iPSCs which could be used for high throughput compound
screening. This cell-specific signature will contribute to the identification and screening of novel
treatments for this life-threatening disease.
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ABSTRACT
We sought to identify the impacts of Friedreich’s ataxia (FRDA) on cardiomyocytes. FRDA is an autosomal
recessive degenerative condition with neuronal and non‐neuronal manifestations, the latter including
progressive cardiomyopathy of the left ventricle, the leading cause of death in FRDA. Little is known about the
cellular pathogenesis of FRDA in cardiomyocytes. Induced pluripotent stem cells (iPSCs) were derived from
three FRDA individuals with characterized GAA repeats. The cells were differentiated into cardiomyocytes to
assess phenotypes. FRDA iPSC‐ cardiomyocytes retained low levels of FRATAXIN (FXN) mRNA and protein.
Electrophysiology revealed an increased variation of FRDA‐ cardiomyocyte beating rates which was prevented
by addition of nifedipine, suggestive of a calcium handling deficiency. Finally, calcium imaging was performed
and we identified small amplitude, diastolic and systolic calcium transients confirming a deficiency in calcium
handling. We defined a robust FRDA cardiac‐specific electrophysiological profile in patient‐derived iPSCs which
could be used for high throughput compound screening. This cell‐specific signature will contribute to the
identification and screening of novel treatments for this life‐threatening disease.
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INTRODUCTION
FRDA is an autosomal recessive degenerative condition
with neuronal and non-neuronal manifestations [1].
Cardiomyopathy is detected in two thirds of individuals
with FRDA [2-4]. Individuals with FRDA generally
present with progressive cardiomyopathy of the left
ventricle, which is the leading cause of death in FRDA
due to arrhythmias and/or heart failure [5, 6]. Little is
known of the cellular impacts of FRDA in the heart, but
cardiomyocyte necrosis and cellular fibrosis have been
identified [6, 7]. Systolic function generally remains
normal until late in disease progression [8]. In
approximately 96% of affected individuals, FRDA is
due to homozygosity for an unstable expanded GAA
repeat mutation in the first intron of FXN resulting in
reduced expression of the nuclear-encoded mitochondrial protein FXN [9-11]. Despite the identification
of FXN, its precise role in FRDA pathogenesis remains
elusive and remarkably little is known about the
molecular pathology of cardiomyocytes in FRDA [12].

ejection fraction (60%), moderate increase in relative
wall thickness (RWT), severe dilatation of the left
atrium (typical FRDA cardiomyopathy) and FA9: low
normal ejection fraction (50%), increased RWT,
borderline increase in left atrial size (typical FRDA
cardiomyopathy).

Human iPSCs [13-15] have been derived from
individuals with FRDA [12, 16-19]. Morphological
abnormalities and a disorganized mitochondrial network
in iPSC-derived- cardiomyocytes have been identified
[16, 19]. There are no abnormalities under basal
conditions, when cultivated in the presence of iron,
cellular hypertrophy occurs [19]. However, more
detailed functional studies are needed to characterize the
cardiomyocytes from FRDA iPSCs. Here, we derived
FRDA iPSCs to assess the electro-physiological and
calcium (Ca2+) cycling properties of cardiomyocytes, to
identify potential mechanisms underlying the cardiomyopathy observed in FRDA.

RESULTS
Generation of three FRDA-iPSC
differentiation into cardiomyocytes

lines

and

We generated FRDA-iPSC lines from three individuals
with different GAA length repeat numbers (Table 1).
We also collected data regarding disease severity as
measured by the Friedreich Ataxia Rating Scale (FARS)
[20]. The FARS is scored out of 167, a higher score
indicating greater disease severity. Clinical parameters
of individuals from whom the lines were derived are as
follows: FA6 (female; GAA1 1077, GAA2 1077; FARS
score 96.5); FA8 (male; GAA1 476, GAA2 545; FARS
score 64.5); FA9 (male; GAA1 733, GAA2 943; FARS
score 118). The individuals with FRDA from which
iPSCs were derived presented with the following
cardiac phenotypes: FA6: normal ejection fraction
(55%), normal ventricular wall thickness, mildly dilated
left atrium (mild cardiomyopathy); FA8: normal
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Figure 1. Generation of iPSC lines from FRDA‐patients.
Immunostaining of FA6 CL1 (A, D), CL2 (B, E), CL3 (C, F) for OCT4 (A‐
C) and TRA‐1‐60 (D‐F); FA8 CL1 (G, J), CL2 (H, K), CL3 (I, L) for OCT4
(G‐I) and TRA‐1‐60 (J‐L); FA9 CL1 (M, P), CL2 (N, Q), CL3 (O, R) for
OCT4 (M‐O) and TRA‐1‐60 (P‐R). (S) Negative isotype. Cells were
counterstained with DAPI (blue). Scale bars: 50 μm.
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We used nucleofection to deliver episomal vectors
containing OCT4, SOX2, KLF4, L-MYC, LIN28,
shRNA against p53 and eGFP into fibroblasts.
Pluripotent clones were expanded and three clones
were selected for each patient (CL1-3). All clones
expressed the pluripotency markers OCT4 and TRA-160 (Fig.1A-S). The intron 1 FXN GAA expansions
were measured for all fibroblasts and iPSC clones
(Table 1, Suppl. Fig. 1). As reported for other FRDA
iPSCs [16-18], we observed similar repeat numbers as

well as contractions and expansions for all lines, with
slight variations between clones of the same line
(Table 1). Importantly, the patient-derived iPSC lines
each maintained the reduced FXN mRNA expression
that is characteristic of FRDA, when compared to
control cells (Fig. 2A). The iPSCs were karyotypically
normal (data not shown), and pluripotent, being able to
differentiate into cells of the three germ layers as
assessed by embryoid body (EB) formation (Suppl.
Fig. 2-4).

Table 1. GAA repeats (GAA1/GAA2). GAA1: smaller allele repeats; GAA2: longer allele repeats. F:
Female, M: Male. FARS: Friedreich Ataxia Rating Scale.
Patient, predicted
Fibroblasts
CL1
CL2
CL3

FA6 (F, FARS: 96.5)
1077/1077
854/247
893/281
887/273
980/294

FA8 (M, FARS: 64.5)
476/545
481/576
579
593/323
576/315

FA9 (M, FARS:118)
733/943
788/109
963
980/383
991

Figure 2. FRDA‐iPSCs and ‐ cardiomyocytes retain low levels of FXN and are mainly of ventricular phenotype. (A, B) qPCR
and (C) dipstick analysis showing low levels of FXN mRNA (A, B) and protein (C) in undifferentiated cells (A) and their cardiac derivatives
(B, C). Significance was assessed by comparing FRDA‐iPSCs to undifferentiated H9 controls (A) or FRDA‐iPSC derived cardiomyocytes to H9
derived cardiomyocyte controls (B, C). One‐way ANOVA followed by Bonferroni’s multiple comparison test, ** p<0.01 , **** p< 0.0001.
(D) qPCR analysis of cardiomyocytes showing significantly higher expression of MYL2 than MYL7 across all cell lines (p<0.05, paired t‐test).
(A‐D) Data are mean ± SEM of combined clones or 3 individual experiments, normalized to ACTB and relative to undifferentiated cells (A,
B, D) or normalized to the control line cardiomyocyte (C). (E‐G) Representative images of FA6‐ cardiomyocytes (E), FA8‐ cardiomyocytes
(F) and FA9‐ cardiomyocytes (G) for MYL2/MLC2v (green), MYL7/MLC2a (red, weak or absent) and counterstained with DAPI (blue).
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All lines were differentiated into cardiomyocytes using
a small-molecule based approach [21]. In basal
conditions, FRDA- cardiomyocytes were not hypertrophic, as assessed by the absence of nuclear
localisation of NFATC4 (Suppl. Fig. 5), a nuclear
translocation known to be a marker of hypertrophy [22,
23]. The FRDA- cardiomyocytes retained low levels of
FXN mRNA and protein (Fig. 2B, C). Phenotypes were
assessed at day 35. At this stage, transcripts of MYL2
were significantly higher than MYL7 across all cell lines
(Fig. 2D). The cardiomyocytes expressed MYL2/MLC2v
protein and MYL7/MLC2a was rarely observed (Fig.
2E-G). Taken together, these data suggest a ventricular
phenotype in the cardiomyocytes that were generated
with minimal atrial cardiomyocytes for all lines (Fig.
2D-G) [19, 24].
FRDA-iPSC-derived
cardiomyocytes
phenotypic abnormalities

display

The Multi Electrode Array (MEA) revealed electrophysiological anomalies in the different FRDA lines,
with consistent effects in all three clones of all FRDA
lines. All FRDA lines showed similar basal beat rates

(30-40 beat per minute, Fig. 3A) which were slower
than control cardiomyocytes. All lines showed similar
corrected extracellular field potential durations (cFPD,
Fig. 3B). We assessed the root of the mean of the sum
of the square of the difference in the RR interval
(RMSSD), that measures the variation in a consecutive
series of intervals between field potentials (Fig. 3C, D).
FRDA-iPSC-derived cardiomyocytes showed significantly increased RMSSD under basal conditions and
when treated with isoprenaline (10-6 M, Fig. 3C, D).
Elevated RMSSD in cultured cardiomyocytes, including
those derived from PSCs, is indicative of Ca2+ handling
abnormalities. When FRDA- cardiomyocytes were
examined under basal conditions or following treatment
with isoprenaline, application of nifedipine (10-8 M),
which partially blocks L-type Ca2+ channels, prevented
an increase in RMSSD, thus confirming that Ca2+ is
responsible for the abnormal beat rate variability in line
with other studies on PSC-derived cardiomyocytes. In
contrast, blocking K+ channels with TEA (10-8 M) did
not modify the effect of isoprenaline, with an increase
in RMSSD and in cFPD (data not shown). Altogether,
these data suggest that FRDA- cardiomyocytes display
a significant increase in beat rate variability, demons-

Figure 3. Assessment of phenotypes in FRDA iPSC‐derived cardiomyocytes. (A) Beating rates (beats per minute, BPM), (B)
corrected extracellular field potential durations (cFPD) and (C, D) the root of the mean of the sum of the square of the difference in the
RR interval (RMSSD) (ms). Data shows RMSSD at basal (C) and 10‐6M (D) isoprenaline ± nifedipine (NIF). (E) Representative Ca2+
transients. (F) Diastolic, (G) systolic and (H) amplitude Ca2+ in Control and FRDA‐ cardiomyocytes. (A‐D) Data are mean ± SEM of
combined values of 3 clones of each line (n=3 per line) and as a pool of all 3 clones of all FRDA lines (n=9 FRDA independent samples)
and control cardiomyocytes (n=6). (F‐H) Data are mean ± SEM of combined values control cardiomyocytes (n=5), of all 3 clones of each
FRDA line (n=8‐14 per line) and as a pool of all 3 clones of all FRDA lines (n=35 FRDA independent samples). Statistics: (A‐D, F‐H) One‐
way ANOVA followed by Bonferroni’s multiple comparison test, * p<0.05, **, p<0.01, ***, P<0.001.
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trating a potential for cardiac dysfunction, compared to
the control cardiomyocytes. These data also suggest that
impairment in Ca2+ handling is responsible for the
observed electrophysiological phenotype. This was
confirmed by assessing Ca2+ transients. In the FRDAcardiomyocytes significantly lower diastolic and
systolic Ca2+ levels and reduced transient amplitude
signals were observed compared with control cardiomyocytes (Fig. 3 E-H). Collectively, our data
demonstrates a Ca2+ handling impairment in the FRDA
cardiomyocytes.

DISCUSSION
Our data reveal electrophysiological anomalies in
FRDA iPSC derived - cardiomyocytes, with an increase
beat rate variability. As partial inhibition of L-type Ca2+
channels with nifedipine abolished this electrophysiological phenotype, it demonstrates that the
electrophysiological impairment is due to Ca2+ handling
abnormalities. As cFPD were not increased in the
FRDA iPSC-derived cardiomyocytes, Ca2+ overload is
unlikely. This was confirmed with measurement of Ca2+
cycling, which identified that FRDA cardiomyocytes
show low Ca2+ transients. Yet, it is difficult to reconcile
how the increased beat rate variability is remedied by
the Ca2+ channel blocker nifedipine, when the Ca2+
transients suggest that cytosolic Ca2+ levels were
already lower than in the controls. It is feasible that in
the context of mitochondrial dysfunction in FRDA,
ATP-dependent ion channels, particularly sarco/endoplasmic reticulum Ca2+-ATPase, may lack the required
ATP for proper functioning, leading to reduced Ca2+
storage in the sarcoplasmic reticulum and therefore
reduced Ca2+-induced Ca2+ release during an action
potential. There have been two previous reports
describing phenotypes in FRDA iPSC-derived cardiomyocytes, including Ca2+ handling deficiencies, albeit
in the presence of exogenous iron [19, 24]. Yet, whilst
iron accumulation is generally regarded as a common
feature of FRDA pathogenesis, there is scant evidence
of iron accumulation in the heart [25]. The data reported
here provide the first demonstration of a phenotypic
abnormality in cardio-myocytes derived from FRDAiPSCs without such artificial iron treatment or external
stimulus. This suggests that reduced FXN causes
dysfunction in cardiomyocytes prior to events such as
accumulation of iron. The establishment of a phenotype,
itself reversible by selective treatment with nifedipine,
now forms a platform to screen molecules known to
modify FXN and directly assess their impact on human
FRDA- cardio-myocytes, and hence contribute to the
discovery of specific treatments for FRDA. Indeed,
cardiomyocytes derived from patient iPSCs show clear
phenotypic abnormalities, consisting of an increase in
beat rate variability and reduced Ca2+ transients.
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Although not assessed here, mitochondrial oxidative
phosphorylation (OXPHOS) deficiencies, which are
reported in FRDA [26], can reduce mitochondrial Ca2+
uptake and ATP production [27, 28]. It has also been
suggested that mitochondrial OXPHOS defects in
FRDA could be an indirect consequence of oxidative
stress [29]. Given the impact of reduced Ca2+ levels on
mitochondrial function, our data suggests that Ca2+
handling defects could also contribute to the perceived
OXPHOS deficiencies. Treatment of FRDAcardiomyocytes with nifedipine improved phenotypes
detected by MEA. Whilst it may seem contradictory
that partially inhibiting L-type Ca2+ channels improves
cardio-myocytes with low Ca2+ levels, it is possible that
nifedipine is acting on other Ca2+ channels
independently [30]. This may either mask or restore the
Ca2+ levels in the cardiomyocytes [31]. Further indepth investigations directed at Ca2+ handling
machinery of FRDA iPSC-derived cardiomyocytes
should unravel the mechanisms behind these phenotypes and identify therapeutic targets.
It might be counterintuitive to relate an increased
RMSSD in cultured cardiomyocytes to patient phenotypes. Indeed, patients presenting with cardiomyopathy,
including FRDA patients, demonstrate reduced heart
rate variability compared to healthy individuals [32].
However, these measures in patients relate more to the
function of the autonomic nervous system rather than
the function of cardiomyocytes. To our knowledge only
two studies have assessed Ca2+ levels in post-mortem
FRDA hearts, both describing elevated right ventricle
Ca2+ levels, and low-to-normal left ventricle levels in
the earlier report versus somewhat elevated left
ventricle Ca2+ in a recent report [25, 33]. It is however
feasible that the FRDA-iPSC derived cardiomyocytes
are useful in identifying pathophysiology underlying or
preceding the cardiomyopathy observed in FRDA.
Importantly, our data clearly indicates that FRDA iPSCderived cardiomyocytes can be used for screening of
compounds able to alter or reverse phenotypes, in
human cells, hence providing a novel and unique tool
for FRDA research.

METHODS
Ethics Committee approvals
All experimental work performed in this study was
approved by the Human Research Ethics Committees of
the University of Melbourne (0829937, 0605017,
1545383, 1545394) meeting the requirements of the
National Health & Medical Research Council of
Australia (NHMRC) and conforming to the
Declarations of Helsinki.

AGING

Biopsies
The biopsy measured approximately 2–3 mm in
diameter and was taken via a needle from the inside of
the forearm by a qualified clinician. The risks
associated with a skin biopsy are small, however the
risks of bleeding and infection were minimised through
careful technique, the use of antiseptics and sterile
instruments. Minimal pain was experienced at the site
once the anaesthetic had worn off and none of the
individuals reported any complications following this
procedure.
iPSC Generation
iPSCs were generated using skin fibroblasts obtained
from FRDA (FA6, FA8 and FA9) and control subjects
over the age of 18 years by an episomal method as
described previously [34]. Reprogramming was
performed on passage 8-10 fibroblasts by nucleofection
with episomal vectors expressing OCT4, SOX2, KLF4,
L-MYC, LIN28 and shRNA against p53 [35].
Maintenance of pluripotent stem cells (PSCs) and
cardiomyocyte differentiation
The FRDA-iPSC lines FA6, FA8, FA9 and the control
human embryonic stem cell (hESC) line H9 (WiCell)
[36] were maintained in the undifferentiated state using
TeSR-E8 medium (Stem Cell Tech). H9 was used as a
control as the line is very well described; H9-derived
cardiomyo-cytes are structurally and functionally
similar to iPSC-derived cardiomyocytes [23, 37, 38],
and have been used as a control for overexpression of
mutant MYH7 for modelling cardiomyopathy [23].
hESCs are known to be molecularly and functionally
equivalent to iPSCs [39], hence can serve as adequate
controls to iPSCs. Embryoid bodies (EB) were obtained
as described [40]. In the functional MEA experiments,
the control iPSC line, iPSC(Foreskin)-2 [41] was also
used, in order to ensure that variations observed
between FRDA iPSCs lines and H9 cells were not
peculiar
to
the
latter.
Differentiation
into
cardiomyocytes was achieved using a small moleculebased approach, with initial exposure to GSKβ
inhibitors (1 µM BIO, 3.5 µM CHIR99021) for 2 days,
followed by addition of XAV939 (2 µM) and KY02111
(10 µM) from days 3-8, in IMDM containing 4 mM Lglutamine, 25 mM HEPES, 1% non-essential amino
acids, 4 mg/mL human albumin, 100 µM 2mercaptoethanol, 25 U/mL penicillin, 25 µg/mL
streptomycin (all from Thermo Fisher Scientific) and
120 µg/mL L-ascorbic acid sesquimagnesium salt
(Sigma Aldrich) [21]. Following two weeks of
differentiation in adherent culture, cells were harvested
and grown as floating spheres for an additional two
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weeks in cardiac differentiation medium containing 0.4
mg/mL albumin and 12 µg/mL L-ascorbic acid
sesquimagnesium salt. For subsequent work, cells were
dissociated with a protease mixture containing 0.1%
collagenase I (Wako Pure Chemicals), 0.25% trypsin
and 1 U/mL DNase I (Thermo Fisher Scientific) in a
buffer consisting of 116 mM NaCl, 20 mM HEPES,
12.5 mM NaH2PO4, 5.6 mM glucose, 5.4 mM KCl, 0.8
mM MgSO4, pH 7.35 (all from Sigma Aldrich).
Dissociated cardiomyocytes were plated as monolayers
on laminin- or Matrigel-coated plates or slides in
albumin- and ascorbic acid-free medium. To assess
differentiation, we performed qPCR and/or immunostaining of the cardiac markers actin alpha cardiac
muscle 1 (ACTC1), troponin T type 2 (TNNT2),
troponin I type 3 (TNNI3) and NK2 transcription factor
related locus 5 (NKX2.5) to assess presence of
cardiomyocytes, and atrial and ventricular myosin light
chain 2 (MLC2a/ MLC2v) to assess the proportion of
atrial and ventricular cardiomyocytes. TNN and ACTC
staining were also used to assess cardiomyocyte
morphology. Nuclear factor of activated T cells 4
(NFATC4) was used to assess the presence of
hypertrophy in the cardiomyocytes. A visual assessment
of beating cells further confirmed the cardiac
phenotype.
Real-time quantitative RT-PCR
Total RNA was extracted from cells using the RNeasy
Mini Kit (Qiagen, Hilden, Germany), converted to cDNA
using High Capacity cDNA Reverse Transcriptase Kit
(Applied Biosystems, Foster City, CA). Q-PCRs were
carried out using TaqMan Universal master mix and the
7900HT Fast Real-Time PCR system using TaqMan
gene expression assay for FXN (Hs00175940_m1),
MLC2a/MYL7
(Hs01085598_g1),
MLC2v/MYL2,
(Hs00166405_m1), ACTC1 (Hs01109515_m1), TNNT2
(Hs00165960_m1), TNNI3 (Hs00165957_m1), NKX2.5
(Hs00231763_m1),
Glyceraldehyde
3-phosphate
dehydrogenase (Human GAPDH, Hs99999905_m1),
beta-actin (ACTB; Hs99999903_m1) (all from Applied
Biosystems). The relative quantitation was achieved by
applying the comparative CT method (ΔΔCT) whereby
the mRNA levels were normalized against the level of
GAPDH or ACTB and the control group was used as the
calibrator.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde (PFA) or
ethanol (OCT-4), blocked in 10% fetal calf serum-PBT,
and immunostained using the following antibodies:
mouse anti-OCT3/4 (Santa Cruz Biotechnology), mouse
anti-TRA-1-60 (Millipore), mouse anti-NESTIN
(Millipore), rabbit anti-alpha-fetoprotein (AFP, Dako),
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mouse anti-smooth muscle actin (SMA, R&D systems),
mouse anti-ACTC1 (Abcam), rabbit anti-NFATc4
(Santa Cruz), rabbit anti-MYL2 (Proteintech), mouse
anti-MYL7 (abcam). Cells were then immunostained
with the appropriate conjugated secondary antibodies
(Alexa Fluor 568 or 488, Molecular probes-Invitrogen).
Nuclei were counter-stained with Hoechst-33342
(Sigma-Aldrich) or DAPI (Invitrogen). Specificity of
the staining was verified by the absence of staining in
negative controls consisting of the appropriate negative
control immunoglobulin fraction (Dako).
GAA expansion analysis
Genomic DNA for GAA expansion analyses was
extracted from fibroblasts and iPSCs using the QIAamp
DNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. The concentration and
purity of the genomic DNA were assessed using a
Nanodrop1000 spectrophotometer (Thermo Fisher
Scientific). The size of the GAA expansion in intron 1
of the FXN gene was determined by PCR using the
Expand Long Range dNTPack (Roche, Australia) as
recommended with 20 ng template DNA, 0.4 μM of
EXP-Bam-F 5′AAGGAAGTGGTAGAGGGTGTTTCA
CGAGGA3′ and EXP-Bam-R 5′TTTGGATCCAACTC
TGCTGACAACCCATGCTGTCCACA3′ primers and
1x Q solution (QIAGEN, Australia). PCR products
were electrophoresed on a 1% (w/v) agarose, 1x TAE
gel alongside standard DNA markers (200 bp ladder,
Promega). Size determination was performed using
GeneTools software from SynGene, Synoptics (In Vitro
Technologies). The positive control (BAC clone RP11265B8) and non-expanded alleles in the normal range
yielded an 810 bp fragment. The hESC H9, BG01V
(ATCC) and the human fibroblast feeders WS1 (ATCC)
were included as negative controls for FXN expansion.
Dipstick of FXN expression
Dipstick assay for FXN (Mitosciences) was performed
as per the manufacturer’s instructions [42]. This method
allows the quantification of FXN by using two specific
monoclonal antibodies against different antigens of
FXN, in a sandwich ELISA assay. Briefly, one capture
antibody bound to a nitrocellulose membrane captures
FXN, and a detector antibody conjugated to gold
provides a signal when bound to the complex of capture
antibody-FXN-detector antibody. Levels of FXN are
then detected and quantified by an increased signal
intensity.
Electrophysiological characterization
Electrophysiological measurements of cardiomyocytes
seeded onto laminin-coated 60 electrodes MEA plates
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were performed by MEA (Multichannel Systems,
Reutlingen, Germany) as previously described [40].
Cells were incubated at 370C in cardiac differentiation
medium without albumin and ascorbic acid. Basic
receptor and ion channel function were assessed by
treatment of cardiomyocytes with nifedipine (inhibitor
of L-type Ca2+ channel) and isoprenaline (β-adrenergic
receptor agonist) (Sigma-Aldrich). Extracellular field
potentials were recorded at baseline and 1 minute after
addition of drugs. Data were analyzed offline with MC
Rack version 4.3.5 software for beating rate, inter-beat
(RR) interval and extracellular field potential duration
(FPD). RR interval was defined as the time elapsing
between two consecutive beats, and FPD was defined as
the time interval between the initial deflection of the
field potential and the maximal local T wave. To avoid
the influence of beat frequency on FPD, FPD measurements were normalized (corrected FPD, cFPD) with the
Bazett’s correction formula: cFPD = FPD/√(RR
interval) [43]. Data were expressed as percentage
change from baseline with baseline set to 100%. Root of
the mean of the sum of the square of the difference in
the RR interval (RMSSD) was also assessed.
Intracellular Ca2+ and contractility measurements
Intracellular Ca2+ was measured by microfluorimetry
(Ionoptix MA, USA). Cells were loaded with the Ca2+
fluorescent dye FURA-2/AM (5 μM, 10 min incubation
at room temperature, Molecular Probes). They were
placed in a chamber mounted on the stage of a Motec
AE31 inverted fluorescence microscope immersed in
medium (IMDM without phenol red, containing 4 mM Lglutamine, 25 mM HEPES, 1% non-essential amino
acids, 25 U/mL penicillin and 25 µg/mL streptomycin;
the total concentration of Ca2+ in the medium was 1.5
mM), at room temperature and stimulated to contract at
1Hz. Excitation light at 340 nm and 380 nm was
provided by a 75-watt xenon lamp and filter wheel.
Emitted fluorescence (510 nm) was recorded by a
photomultiplier tube, with the output current converted to
voltage and digitized for subsequent analysis. Background correction was undertaken at the completion of
each cell recording and incorporated into analysis
protocol. The following Ca2+ parameters were measured:
diastolic Ca2+, systolic Ca2+, amplitude of the Ca2+ transient and time constant of decay of the Ca2+ transient (tau).
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). All statistical analyses and graphical data
were generated using Graphpad Prism software (v5.04,
www.graphpad.com). Statistical methods utilized were
one-way ANOVA followed Tukey’s or Bonferroni’s
multiple comparisons test and t-test. Statistical

AGING

significance was established as *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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SUPPLEMENTARY MATERIAL

Supplementary Figure 1. GAA expansion PCR. The size of the GAA expansion
was determined in control (H9, BG01V, WS1) and FRDA cells (FA6, FA8 and FA9) by
comparison to standard DNA markers (MW). Genomic DNA isolated from
fibroblasts (Fibro) and iPSC clones (CL) 1‐3 were used in long range PCR of the first
intron of FXN. Non‐expanded alleles yield a product of 810 bp. Positive (Human
embryonic stem cell lines H9 and BG01V, human fibroblast WS1, BACRP11‐265B8
DNA containing the FXN gene, Control genomic (g)DNA and FRDA gDNA) and
negative controls (no DNA) were included.

Supplementary Figure 2. Representative germ layer immunostaining of FA6‐EBs. FA6 Clone 1‐3
(A‐C, D‐F, G‐H) demonstrate pluripotency by positive staining for markers of each embryonic germ layer;
endoderm (AFP; A, D, G), mesoderm (SMA; B, E, H) and ectoderm (nestin; C, F, I). Scale bars = 50 μm.
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Supplementary Figure 3. Representative germ layer immunostaining of FA8‐EBs. FA8 Clone 1‐3
(A‐C, D‐F, G‐H) demonstrate pluripotency by positive staining for markers of each embryonic germ layer;
endoderm (AFP; A, D, G), mesoderm (SMA; B, E, H) and ectoderm (nestin; C, F, I). Scale bars = 50 μm.

Supplementary Figure 4. Representative germ layer immunostaining of FA9‐EBs. FA9 Clone 1‐3
(A‐C, D‐F, G‐H) demonstrate pluripotency by positive staining for markers of each embryonic germ layer;
endoderm (AFP; A, D, G), mesoderm (SMA; B, E, H) and ectoderm (nestin; C, F, I). Scale bars = 50 μm.
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Supplementary Figure 5. Assessment of hypertrophy in FRDA‐cardiomyocytes. FA8‐cardiomyocytes 35 days post‐
differentiation untreated (A‐D) or treated with 1µM isoprenaline to induce hypertrophy (E‐H), immunostained for troponin
(A, E); NFATc4 (B, F), counterstained with DAPI (C, G) and merged (D, H). Nuclear localisation of NFATc4 is indicative of
hypertrophy and some are illustrated with arrows. Data presented on FA8 cells are representative of all cell lines tested.
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